CDK4PPI awarded « 2019 best academic project » by the MATWIN international board

CDK4 kinase is a key cell cycle regulator and attractive pharmacological target for development of anticancer therapeutics. While recently marketed anti-CDK4 drugs present limitations in terms of efficacy, selectivity and toxixity, due to their conventional, ATP-competitive mechanism of action, the CDK4 team project gathering May Morris and Frederic Bihel has identified a promising family of compounds that target CDK4 in a different fashion (allosteric inhibitors).

Among the nine projects interviewed this year, the CDK4 project proposed by May Morris and Frédéric Bihel, was awarded “Best project – academic team” by the MATWIN International Board and has exceptionally received a prize of 60k€ to support the project’s development.

To access the complete press release, click here -> press release